New Delhi (NVI): The Hyderabad-based Bharat Biotech today announced the successful completion of volunteer enrollment for Phase-3 clinical trials of its indigenous coronavirus vaccine called COVAXIN.
Taking to Twitter, the vaccine manufacturing company gave the information. “Announcing successful completion of volunteer enrolment for Phase-3 Clinical trials of COVAXIN,” Bharat Biotech tweeted.
— BharatBiotech (@BharatBiotech) January 7, 2021
Suchitra Ella, Joint Managing Director Bharat Biotech International Ltd took to Twitter in this regard and wrote, “COVAXIN successfully completes Phase 3 clinical trials enrolment of 25,800 volunteers.”
“We sincerely express our gratitude to clinical trial sites, Principle Investigators & healthcare workers for their relentless support and trust in our Public-Private Partnership vaccine discovery. My deep appreciation to all the volunteers for reposing trust and expressing Pro Vaccine Public Health Volunteerism in the Phase-3 Clinical Trials of India’s 1′ fully indigenous COVID-19 Vaccine,” she said in a statement.
This announcement comes two days after Bharat Biotech pledged to work together with the Serum Institute Of India to develop, manufacture and supply the COVID-19 vaccines in the country.
In the statement posted on their respective Twitter accounts, the companies said Serum Institute Chief Executive Officer Adar Poonawalla and Bharat Biotech Chairman Krishna Ella communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines.
Earlier, Phase-1 and Phase-2 clinical trials of COVAXIN were evaluated in approximately 1000 subjects and the results have demonstrated that the vaccine is safe and provides a robust immune response.
COVAXIN is India’s indigenous COVID-19 vaccine by Bharat Biotech and is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), the company had said in its statement.